Chunli Medical (688236.SH) reported first-half results, net profit of 79.0261 million yuan, a year-on-year decrease of 37.32%

According to Zhitong Finance App News, Chunli Healthcare (688236.SH) released its 2024 semi-annual report. During the reporting period, the company achieved operating income of 380 million yuan, a decrease of 29.70%; net profit attributable to shareholders of listed companies was 79.0261 million yuan, a year-on-year decrease of 37.32%; net profit attributable to shareholders of listed companies deducted 65.915 million yuan in net profit and loss, a year-on-year decrease of 40.25%; basic earnings per share were 0.21 yuan/share.

The company plans to distribute a cash dividend of 0.83 yuan (tax included) for every 10 shares to all shareholders.

The company has always focused on the R&D, production and sales of implantable orthopedic medical devices. After years of research and development, the company has mastered many core technologies. The core technologies the company has mastered include general upgrade technology and unique technology. Among them, general upgrade technology is a technology based on general technology or necessary technology, combined with skeletal characteristics, clinical needs and feedback from Chinese people to optimize and upgrade product performance or process; unique technology is the core technology achieved by the company through continuous research and research by relevant personnel based on R&D experience and future R&D plans. The core technologies mastered by the company include core hip technology, core knee technology, shoulder and elbow joint core technology, joint bone defect technology, spinal core technology, core trauma technology, sports medicine core technology, PRP core technology, core dental technology, etc.

As of June 30, 2024, the company has registered 155 medical devices (covering products such as joints, spine, sports medicine, trauma, oral cavity, PRP, surgical robots, etc.) in China. The acquisition of multi-category registration certificates has further enriched the company's product line, expanded the company's layout in the medical field, and continuously met diversified market and clinical needs, which will enhance the company's overall competitiveness and help further enhance the company's market expansion capabilities.